RVPH has one compound they’re actively working on. IBRX has 16 or 17 trials ongoing with several of them at late stage. The FDA didn’t have issues with IBRX’s bladder cancer drug or the results. I think IBRX’s CEO, Patrick Soon-Shiong, has a meeting w/FDA to find out exactly what needs to happen with the manufacturing facilities. Then, he has to decide how much money and time that will take, so he can reapply for permission to market the drug. Then, he’ll decide whether to foot the bill himself or partner w/big pharma before the drug gets approved. Of course, he wants to partner >after< the bladder drug is approved to get full value. My take is he’ll foot the bill himself (he’s already pumped $700 million into the company), wait for FDA approval, and, then, partner w/big pharma. If something was seriously flawed with IBRX’s drug, the stock would be trading under a dollar…instead of where it was two weeks ago. Finally, the real losers today are the patients who could’ve benefited from this medication. The FDA should be completely gutted and retooled.